RU2194517C1 - External antiedematous product - Google Patents

Abstract

FIELD: medicine, curative cosmetology. SUBSTANCE: the innovation deals with manufacturing curative cosmetic products in the form of ointments, creams, emulsions, lotions, gels used as an antiedematous product. The suggested external antiedematous product contains a foundation, a target phosphonate additive, soluble magnesium salt. It, additionally, could contain medicinal and/or aromatizing and/or biologically active additives. EFFECT: higher efficiency. 2 cl

Description

 The invention relates to the field of cosmetology and medicine and can be used for the manufacture of medical and cosmetic products in the form of ointments, creams, emulsions, lotions, gels used as decongestants.

 External therapeutic and cosmetic products manufactured in various forms, for example, in the form of creams, ointments, gels, etc., always contain a physiologically acceptable base and various targeted additives. Components such as a lipid carrier, emulsifier, thickener, preservative, and solvent are usually introduced into the base composition. In the most common application of the already known standard cosmetic or therapeutic bases, changes are introduced into the composition of the additives.

 The most widely used additives in medical and cosmetic products are medicines, biologically active additives, essential oils, fruit acids, flavors, colorants, various chemical compounds, both organic and inorganic, of synthetic or natural origin.

 Of particular interest to the new invention are known formulations containing magnesium salts. It is known from the prior art the use of soluble magnesium salts, namely magnesium chloride, magnesium sulfate, magnesium acetate in the compositions of cosmetic and therapeutic agents used, for example, as part of facial cleansing lotions / Japan, patent 62-258312; A 61 K 7/00, 1987; S.A. 1988, 108: 209994 /, salt creams of nourishing action / Japan, patent 8175962; A 61 K 7/48, 1996; C.A. 1996, 125: 177006 /, as part of cosmetics that prevent dry skin / Japan, patent 62-209010; A 61 K 7/00, 1987; S.A. 1988, 108: 101113 /. However, the use of magnesium salts in the composition of decongestants has not been identified.

 As a decongestant, as well as a means for treating other diseases, an already known composition is used, selected as a prototype for the new composition.

 This external agent for the treatment of neurological diseases, diseases of the musculoskeletal system with pain and swelling, contains 0.5-3 wt. % Xidiphon preparation / K, Na salt of 1-hydroxyethylidene biphosphonic acid / and 99.5-97 wt. % of any acceptable basis / RF patent 2101015; A 61 K 31/66, 1998 /. However, the known agent is preferably used in the treatment of neurological diseases and diseases of the musculoskeletal system and is not very effective as a decongestant, therefore, in practice, especially in the field of cosmetology, it is practically not used as an decongestant.

 The new invention is an external decongestant containing a base, a phosphonate additive and soluble magnesium salts with a weight content of magnesium salts of 0.1-30 wt.%, Phosphonate additives of 0.01-10 wt.%. The external agent is in the form of a cream, ointment, gel, emulsion, lotion. The tool may additionally contain medicinal, biologically active, aromatic additives in an effective amount. The new invention differs from the prototype in the content of the target additive - soluble magnesium salt in a certain effective amount / 0.1-30 wt.% /, Which leads to a synergistic decongestant effect, confirmed by clinical studies. As the magnesium salts, any physiologically acceptable salts may be used, such as chloride, acetate, sulfate, etc. The choice of the claimed amounts of magnesium salt content is determined by the effectiveness, the absence of side effects and the stability of the composition. As another effective additive, any physiologically acceptable phosphonate-containing compound or mixture thereof is used. The following known compounds can be used as such a compound: hydroxymethylene bisphosphonic acid and its salts, hydroxyethylidene biphosphonic acid and its salts, phosphonoformic acid and its salts, ethylenediaminetetetramethylphosphonic acid and its salts, etc. These compounds can be included in the amount of 0.01-10 wt.%, Which is determined by the effectiveness and stability of the composition.

 The invention is illustrated below with specific formulations in the form of a cream, ointment, gel, lotion.

 1. An example of the composition of a decongestant cream containing 0.7% magnesium salt and 1.0% phosphonate supplement.

Component - wt.%
The foundation:
Stearin - 2.0
Glycerol Monostearate - 1.5
Higher fatty alcohols C16-C20 - 1.0
Vegetable Oil (Olive) - 6.0
Perfume Oil - 4.0
Anhydrous lanolin - 0.8
Triethanolamine - 1.6
Additives:
Magnesium sulfate 7-water - 0.7
K, Na salt of 1-hydroxyethylidene biphosphonic acid - 1.0
Color extract linden - 1.0
Marshmallow Root Extract - 1.0
Preservative, fragrance - qs

Water - Up to 100%
2. An example of the composition of a decongestant ointment containing 1.5% magnesium salt and 2.0% phosphonate supplement.

Component - wt.%
The foundation:
Glycerol Oleate - 12.0
Potassium dialkyl phosphate 4.0
Vaseline oil - 42.0
Lanolin Anhydrous - 1.0
Additives:
Magnesium sulfate 7-water - 1.5
Ethylenediaminotetramethylphosphonic acid - 2.0
Racemic menthol - 0.5
Preservative - qs

Water - Up to 100%
3. An example of the composition of a decongestant gel containing 1.8% magnesium salt and 2.0% phosphonate supplement.

Component - wt.%
The foundation:
Sodium Alginate - 0.1 - 0.2
Glycerin - 1.0
Additives:
Magnesium chloride 6-water - 1.8
Ethylenediaminotetramethylphosphonic acid - 2.0
Tea Tree Essential Oil - 0.3
Preservative, fragrance, dye - qs

Sodium hydroxide - Up to pH 7.0
Water - Up to 100%
4. An example of the composition of a decongestant lotion containing 0.7% magnesium salt and 0.5% phosphonate supplement.

Component - wt.%
The foundation:
PEG-40 hydrogenated castor oil - 0.1
Sodium carboxymethyl cellulose - 0.1
Propylene glycol - 1.5
Ethyl alcohol - 15.0 - 20.0
Additives:
Magnesium chloride 6-water - 0.7
Oxymethylene bisphosphonic acid - 0.5
Green Tea Extract - 2.0
Lavender essential oil - 0.2
Dye - qs

 Water - Up to 100% g

Claims (2)

1. An external decongestant containing a base and a phosphonate target supplement, characterized in that it further contains soluble magnesium salts in the following weight ratio of the components of the mixture, wt. %:
Phosphonate Target Additive - 0.01-10
Soluble Magnesium Salt - 0.1-30
Basis - Else
2. An external decongestant according to claim 1, characterized in that it is made in the form of an ointment, cream, gel, lotion.  3. The tool according to paragraphs. 1 and 2, characterized in that it further comprises medicinal and / or flavoring and / or biologically active additives.